Evidence map›Paper›PMID 40075322›Full record

ArticleBMC cancer2025

Identifying distinct prognostic and predictive contributions of tumor epithelium versus tumor microenvironment in colorectal cancer.

Mingli Yang, Michael V Nebozhyn, Michael J Schell, Nishant Gandhi, Lance Pflieger, Andrey Loboda, W Jack Pledger, Ramani Soundararajan, Michelle Maurin, Heiman Wang and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Mingli YangDepartment of Surgery, University of South Florida, 560 Channelside Drive, Tampa, FL, 33602, USA. mingliyang@usf.edu.
Michael V NebozhynMerck Research Laboratories, 33 Avenue Louis Pasteur, Boston, MA, 02115, USA.
Michael J SchellDepartment of Biostatistics and Bioinformatics, Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, FL, 33612, USA.
Nishant GandhiMedical Affairs, Caris Life Sciences, 4610 S 44th Pl, Phoenix, AZ, 85040, USA.
Lance PfliegerPhenome Health, 401 Terry Ave N, Seattle, WA, 98109, USA.
Andrey LobodaMerck Research Laboratories, 33 Avenue Louis Pasteur, Boston, MA, 02115, USA.
W Jack PledgerDepartment of Molecular Medicine, University of South Florida, 12901 Bruce B. Downs Boulevard, Tampa, FL, 33612, USA.
Ramani SoundararajanDepartment of Surgery, University of South Florida, 560 Channelside Drive, Tampa, FL, 33602, USA.
Michelle MaurinDepartment of Surgery, University of South Florida, 560 Channelside Drive, Tampa, FL, 33602, USA.
Heiman WangDepartment of Surgery, University of South Florida, 560 Channelside Drive, Tampa, FL, 33602, USA.
Jetsen Rodriguez SilvaDepartment of Surgery, University of South Florida, 560 Channelside Drive, Tampa, FL, 33602, USA.
Ashley AldenDepartment of Surgery, University of South Florida, 560 Channelside Drive, Tampa, FL, 33602, USA.
Domenico CoppolaDepartment of Pathology, Florida Digestive Health Specialists, 10920 Technology Ter, Lakewood Ranch, FL, 34202, USA.
Andrew ElliottMedical Affairs, Caris Life Sciences, 4610 S 44th Pl, Phoenix, AZ, 85040, USA.
George SledgeMedical Affairs, Caris Life Sciences, 4610 S 44th Pl, Phoenix, AZ, 85040, USA.
Moh'd KhushmanDivision of Medical Oncology, Department of Medicine, Washington University, 4590 Nash Way, St. Louis, MO, 63110, USA.
Emil LouDivision of Hematology, Oncology and Transplantation, Department of Medicine and Masonic Cancer Center, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN, 55455, USA.
Sanjay GoelDepartment of Medical Oncology, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson School of Medicine, 195 Little Albany Street, New Brunswick, NJ, 08903, USA.
Timothy J YeatmanDepartment of Surgery, University of South Florida, 560 Channelside Drive, Tampa, FL, 33602, USA. tyeatman@usf.edu.

Funding

CLINCIAL VALIDATION OF APC AND TP53 AS BIOMARKERS FOR CETUXIMAB RESPONSEUH3CA227955 · NCI · UNIVERSITY OF UTAH · PI YEATMAN, TIMOTHY J · 2021 to 2023
$917k
Detection of Colorectal Cancer Adaptive Mutability May Justify Combination of Targeted- and Immune-TherapiesR21CA256372 · NCI · UNIVERSITY OF UTAH · PI YEATMAN, TIMOTHY J · 2021 to 2021
$392k
APC + TP53 Combinatorial Mutations Emerging as Biomarkers to Predict EGFRI SensitivityR21CA255312 · NCI · UNIVERSITY OF UTAH · PI YEATMAN, TIMOTHY J · 2021 to 2022
$385k
NCI NIH HHS R21 CA255312NCI NIH HHS R21 CA256372NCI NIH HHS UH3 CA227955NIH HHS UH3CA227955, R21CA256372 and R21CA255312.
6 · The paper itself

Abstract

backgroundAccumulating evidence has suggested that cancer progression and therapeutic response depend on both tumor epithelium (EPI) and tumor microenvironment (TME). However, the dependency of clinical outcomes on the tumor EPI vs. the TME has neither been clearly defined nor quantified.

methodsWe classified 2373 colorectal cancer (CRC) tumors into the consensus molecular subtypes (CMS1-4) and generated the 10-gene TME

resultsThe TME

conclusionsHere we identified a pair of new, distinct 10-gene signatures (the EPI

Indexed as

Biomarkers, TumorColorectal NeoplasmsTumor MicroenvironmentEpitheliumFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMalePrognosisBiomarkers, TumorCetuximabClinical outcomeColorectal cancerConsensus molecular subtypeEGFR inhibitorGene expression signatureMEK inhibitorPanitumumabTumor epitheliumTumor microenvironment

Identifiers

PMID40075322
PMCPMC11899100

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.